Economic Burden Associated with Major Surgery in Patients with von Willebrand Disease: A United States Retrospective Administrative Database Analysis
Abiola Oladapo,Yanyu Wu,Mei Lu,Sepehr Farahbakhshian,Bruce Ewenstein
DOI: https://doi.org/10.2147/JBM.S320837
2021-08-07
Journal of Blood Medicine
Abstract:Abiola Oladapo, 1 Yanyu Wu, 2 Mei Lu, 3 Sepehr Farahbakhshian, 3 Bruce Ewenstein 2 1 Baxalta US Inc., a Takeda Company, Cambridge, MA, USA; 2 Takeda Development Center Americas, Inc., Cambridge, MA, USA; 3 Takeda Development Center Americas, Inc., Lexington, MA, USA Correspondence: Yanyu Wu Takeda Development Center Americas, Inc., 40 Landsdowne Street, Cambridge, MA, 02139, USA Tel +1 617-955-6408 Email Purpose: To estimate the incremental economic burden of major surgeries in patients with von Willebrand disease (VWD). Patients and Methods: This was a retrospective analysis of the IBM Health MarketScan ® database (2008– 2018). Patients with at least two healthcare visits for VWD in the database who had undergone at least one major surgery unrelated to VWD (identified via International Classification of Diseases, Ninth and Tenth Revisions procedure codes) were included. Patients without VWD with major surgeries were selected from a 1% random database sample. All patients had ≥ 12 months of continuous healthcare plan enrollment before and following their first major surgery. Patients with VWD were matched (1:1) with patients without VWD using propensity score matching. Regression models compared healthcare resource utilization and costs between the matched cohorts over a 12-month period after patients' index major surgery. Results: After propensity score matching, 2972 pairs were selected. Musculoskeletal and digestive surgeries were the two most common major surgeries (patients with VWD, 39.6% and 25.0%; without VWD, 37.1% and 23.4%, respectively). Patients with VWD were significantly more likely (p< 0.0001) to have an inpatient admission (odds ratio = 1.71; 95% confidence interval [CI] 1.52– 1.92) or emergency room visit (odds ratio = 1.41; 95% CI 1.25– 1.59) than patients without VWD. The numbers of inpatient admissions (incidence rate ratio [IRR] = 1.47; 95% CI 1.35– 1.60), emergency room visits (IRR = 1.44; 95% CI 1.31– 1.59), and outpatient visits (IRR = 1.16; 95% CI 1.11– 1.21) per patient were also significantly greater for patients with VWD than for those without VWD (p< 0.0001). Patients with VWD incurred significantly higher (p< 0.0001) total healthcare costs (medical and pharmacy) per patient than patients without VWD ( 30,154.84, respectively). Conclusion: Healthcare resource utilization and associated costs among patients undergoing major surgeries were significantly higher for those with VWD than for patients without VWD. Keywords: bleeding, healthcare costs, retrospective studies, healthcare resource utilization von Willebrand disease (VWD) is an autosomal inherited blood clotting disorder that manifests most commonly as recurrent mild-to-moderate mucocutaneous bleeding and excessive bleeding after surgery or trauma. 1 , 2 Patients with VWD have impaired hemostasis owing to a quantitative or qualitative deficit in von Willebrand factor (VWF), a plasma glycoprotein that mediates platelet adhesion and aggregation and stabilizes coagulation factor VIII (FVIII) in the circulation. 1–4 Although VWD is classified as a rare disease, it is considered the most common bleeding disorder, with an estimated prevalence of between 0.01% and 1.00% depending on the population and diagnostic approach. 5–8 The first-line treatment of bleeding events in patients with VWD is desmopressin, especially in those with type 1 disease, the mildest form. 1–3 Desmopressin increases plasma levels of endogenous VWF and FVIII by provoking the release of stored VWF. 3 For patients with more severe disease (such as those with type 2 subtypes or type 3), severe bleeding events, or an inadequate response to desmopressin, VWF replacement therapies are the mainstay of treatment. 9–11 In patients with VWD who undergo major surgical procedures, the risk of potentially life-threatening hemorrhage means that hemostatic measures to normalize functional VWF and FVIII levels are obligatory. 11–14 Although major surgical procedures impose a clinical and economic burden on patients in general, patients with VWD who undergo major surgery may be exposed to the additional burden of impaired hemostasis. 15 There is a paucity of published data regarding the economic burden associated with major surgical procedures in patien -Abstract Truncated-